Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial

Controlled Clinical Trials

Volumn 24, Issue 2, 2003, Pages 224-243

  Bautista, Oliver M ^a   Kusek, John W ^b   Nyberg Jr , Leroy M ^b   McConnell, John D ^c   Bain, Raymond P ^d   Miller, Gary ^e   Crawford, E David ^e   Kaplan, Steven A ^f   Sihelnik, Stephen A ^g   Brawer, Michael K ^h   Lepor, Hebert ⁱ  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^g Ctr for Urol Care of Berks County   (United States)

^h Northwest Prostate Institute   (United States)

ⁱ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Benign prostatic hyperplasia; BPH progression; Clinical trials; Medical therapy

Indexed keywords

DOXAZOSIN; FINASTERIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MONOTHERAPY; MULTICENTER STUDY; PROSTATE BIOPSY; PROSTATE HYPERTROPHY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SCREENING; STATISTICAL ANALYSIS; TITRIMETRY; TREATMENT OUTCOME; VOLUNTEER;

DATA COLLECTION; DISEASE PROGRESSION; HUMANS; MALE; PATIENT SELECTION; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 0037385072     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(02)00263-5     Document Type: Article

References (57)

1. McConnell J.D., Barry M.J., Bruskewitz R.C.et al. Benign prostatic hyperplasia. diagnosis and treatment. Clinical practice guideline number 8. AHCPR Publication No. 94-0582:1994;Agency for Health Care Policy and Research, Public Service, U.S. Department of Health and Human Services, Rockville, MD.
2. Holtgrewe H.L., Mebust W.K., Dows J.B.et al. Transurethral prostatectomy. practice aspects of the dominant operation in American urology J Urology. 141:1989;248-253.
3. Mebust W.K., Holtgrewe H.L., Cockett A.T.K., Peters P.C., the writing committee Transurethral prostatectomy. immediate and postoperative complications J Urology. 141:1989;243-247.
4. Medical therapy in benign prostatic hyperplasia: full-scale trial. NIH Guide Volume 23, Number 22, June 10, 1994.
5. Lepor H., Gup D.I., Baumann M., Shapiro E. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. Urology. 32(Suppl 6):1988;21-26.
6. Lepor H. The role of alpha blockade in the therapy of benign prostatic hyperplasia. Lepor H., Lawson R.K. Prostate diseases. 1993;170-182 W.B. Saunders, Philadelphia.
7. Kirby R.S., Coppinger S.W.C., Corcoran M.V.et al. Prazosin in the treatment of prostatic obstruction. British J Urology. 60:1987;136-142.
8. McConnell J.D. Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. Urologic Clinics North Am. 17:1990;661-670.
9. The Finasteride Study Group Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate. 22:1993;291-299.
10. Caine M. Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. British J Urology. 50:1978;551-554.
11. Lepor H., Henry D., Laddu A.R. The efficacy and safety of terazosin for the treatment of symptomatic benign prostatic hyperplasia. Prostate. 18:1991;345-355.
12. Lepor H., Auerbach S., Puras-Baez A.et al. A randomized-placebo controlled multi-center study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urology. 148:1992;1467-1474.
13. Brawer M.K., Adams G., Epstein H., Terazosin Benign Prostatic Hyperplasia Study Group Terazosin in the treatment of benign prostatic hyperplasia. Arch Fam Med. 2:1993;929-935.
14. Beisland H.O., Binkowitz B., Brekkan E.et al. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 22:1992;271-277.
15. Gormley G.G., Stoner E., Bruskewitz R.C.et al. for the Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 327:1992;1185-1191.
16. Stoner E., the Finasteride Study Group Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 43:1994;284-294.
17. Treatment of benign prostatic hyperplasia: pilot-study. NIH Guide Volume 21, Number 16, May 1, 1992.
18. Lan K.K.G., Lachin J.M. Implementation of group sequential logrank tests in a maximum duration trial. Biometrics. 46:1990;759-770.
19. Barry M.J., Fowler F.J., O'Leary M.P.et al., the measurement committee of the American Urological Association The American Urological Association symptom index for benign prostatic hyperplasia. J Urology. 148:1992;1549-1557.
20. Barry M.J., Fowler F.J., O'Leary M.P.et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care. 33:1995;AS145-AS155.
21. O'Leary M.P., Fowler F.J., Lenderking W.R.et al. A brief male sexual function inventory for urology. J Urology. 46:1995;697-706.
22. Ware J.E. A new MOS short-form health survey (SF-36). 1988;The Health Institute, New England Medical Center, Boston.
23. Ware J.E., Snow K.K., Kosinski M., Gandek B. SF-36 health survey manual and interpretation guide. 1993;New England Medical Center, The Health Institute, Boston.
24. Wei L.J., Lachin J.M. Properties of the urn randomization in clinical trials. Control Clin Trials. 9:1988;345-364.
25. Kusek J.W., Ahrens A., Burrows P.K.et al. for the MTOPS Research Group. Recruitment for a clinical trial of drug treatment for benign prostatic hyperplasia. Urology. 59:2002;63-67.
26. Burrows P.K., Kusek J.W., McVary K.et al. for the MTOPS Research Group. Recruitment strategies used in the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials. 19(3S):1998;97S.
27. Davis C.E., Applegate W.B., Gordon D.J.et al. An empirical evaluation of the placebo run-in. Control Clin Trials. 16:1995;41-50.
28. Friedman L.M., Furberg C.D., DeMets D.L. Fundamentals of clinical trials. 3rd ed:1998;Springer, New York.
29. Fisher L., Dixon D.O., Herson J.et al. Intention-to-treat in clinical trials. Peace K. Statistical issues in drug research development. 1991;331-350 Marcel Dekker, New York.
30. Lachin J.M. Statistical considerations in the intent-to-treat principle. Control Clin Trials. 21:2000;167-189.
31. Miller R.G. Simultaneous statistical inference. 1981;Springer-Verlag, New York.
32. Jacobsen S.J., Guess H.A., Panser L.et al. A population-based study of health care-seeking behavior for the treatment of urinary symptoms. the Olmstead County study of urinary symptoms and health status among men Arch Fam Med. 2:1993;729-735.
33. Craigen A.A., Hickling J.B., Saunders C.R., Carpenter R.G. Natural history of prostatic obstruction. J Royal College of General Practitioners. 18:1969;226-232.
34. Wasson J.H., Reda D.J., Bruskewitz R.C.et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. New Engl J Med. 332:1995;75-79.
35. Flanigan R.C., Reda D.J., Wasson J.H.et al. Five-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia. J Urology. 160:1998;12-16.
36. Lachin J.M., Foulkes M.A. Evaluation of sample size and power for the analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance and stratification. Biometrics. 42:1986;507-519.
37. Miller R.G. Survival analysis. 1981;John Wiley, New York.
38. Kalbfleisch J.D., Prentice R.L. Statistical analysis of failure time data. 1980;John Wiley, New York.
39. Fleming T.R., Harrington D.P. Counting processes and survival analysis. 1991;John Wiley & Sons, New York.
40. Buckley I.V., James I. Linear regression with censored data. Biometrika. 66:1979;429-436.
41. Wei L.J. Accelerated failure time model. a useful alternative to the Cox regression model in survival analysis Stat Med. 11:1992;1871-1879.
42. McCullagh P. Regression models for ordinal data. J Roy Statist Soc Ser B. 42:1980;109-142.
43. Laird N.M., Ware J.H. Random-effects models for longitudinal data. Biometrics. 38:1982;963-974.
44. Liang K., Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika. 73:1986;13-22.
45. Jenrich R.I., Schluchter M.D. Unbalanced repeated-measures models with structured covariance matrices. Biometrics. 42:1986;805-820.
46. Wei L.J., Lachin J.M. Two-sample asymptotically distribution-free tests for incomplete multivariate observations. JASA. 79:1984;653-661.
47. Lachin J.M., Wei L.J. Estimators and tests in the analysis of non-independent 2×2 tables with partially missing observations. Biometrics. 44:1988;513-528.
48. Lachin J.M. Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations. Stat Med. 11:1992;1151-1170.
49. Lan K.K.G., DeMets D.L. Discrete sequential boundaries for clinical trials. Biometrika. 64:1983;191-199.
50. Halperin M., Lan K.K.G., Ware J.H.et al. An aid to data monitoring in long-term clinical trials. Control Clin Trials. 3:1982;311-323.
51. Lan K.K.G., Simon R., Halperin M. Stochastically curtailed tests in long-term clinical trials. Comm Stat. 1:1983;207-219.
52. Lan K.K.G., Wittes J. The B-value. a tool for monitoring data Biometrics. 44:1988;579-585.
53. Bautista O.M., Bain R.P., Lachin J.M. A flexible stochastic curtailing procedure for the log-rank test. Control Clin Trials. 21:2000;428-439.
54. McConnell J.D., Bruskewitz R., Walsh P.et al. for the Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 338:1998;557-563.
55. Lepor H., Williford W.O., Barry M.J.et al. for the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 335:1996;533-539.
56. Roberts R.O., Jacobsen S.J., Jacobson D.J.et al. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urology. 163:2000;107-113.
57. Rhodes T., Girman C.J., Jacobsen S.J.et al. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urology. 161:1999;1174-1179.